Figure 1. Micrographs of spinal cord motoneurons showing SOD1-immunoreactive inclusions.
Image credit: Forsberg, et. al. 2010 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email [email protected]. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Clinical Trial Grants
Sponsor: Fight MND
Description: These grants support Phase II/III clinical trials of novel, high-potential treatments for MND/ALS within the Australian Clinical Trials Consortium. These grants are awarded with an offer of AUD $500,000 – $1,000,000 (Phase II trial) up to $1,500,000 (Phase III trial) with a project performance of up to 3 years. Applications are open to MND/ALS researchers globally. Australian trial sites mandatory.
Deadline: Letter of Intent due by January 19, 2019.



NEW! Drug Development Grants
Sponsor: Fight MND
Description: These grants support the preclinical research, development and assessment of therapeutics for MND/ALS through to (and including) completion of Phase I clinical trials. These grants are each awarded with an offer of up to AUD $1,000,000 in support available for 3-year projects (Projects with a period of performance of less than 3-years will also be considered). Applications are open to MND/ALS researchers globally.
Deadline: Letter of Intent due by January 19, 2019.



NEW! ALS Research Program Therapeutic Development Award
Sponsor: US Department of Defense CDMRP
Description: The goal of the Amyotrophic Lateral Sclerosis Research Program is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. The program supports post-discovery, preclinical development of therapeutics for ALS. The maximum award is $1,000,000 USD, or $1,250,000 USD if applying under the Therapeutically Relevant Marker Option. Preliminary data including identity and purity of the identified bioactive compound(s) are required. Collaboration with industry is encouraged.
Deadline: Pre-Proposal due by March 22, 2019.



NEW! ALS Research Program Therapeutic Idea Award
Sponsor: US Department of Defense CDMRP
Description: The goal of this program is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. Funding priorities include screening methods or new ideas aimed at ALS drug or treatment discovery still in the early stages of development. A maximum of $500,000 USD will be awarded.
Deadline: Pre-Proposal due by March 22, 2019.



Edward Scolnick Prize in Neuroscience
Description: The Scolnick Prize is awarded annually by the McGovern Institute to recognize outstanding advances in the field of neuroscience. The prize, which is endowed through a gift from Merck to the McGovern Institute, consists of a $150,000 award, plus an inscribed gift.
Deadline: Nominations due by December 15, 2018.



Neuroscience Prize
Sponsor: Gruber Foundation
Description: The Neuroscience Prize honors scientists for major discoveries that have advanced the understanding of the nervous system. The Prize, established in 2004, comprises an engraved gold laureate pin, an unrestricted cash award of $500,000, and a citation describing the achievement for which the recipient is being honored. It is awarded each year to a person or persons chosen by a distinguished advisory board of neuroscience experts from nominations that are received from around the world.
Deadline: Nominations due by December 15, 2018.



Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes
Sponsor: National Center for Advancing Translational Sciences
Description: This Funding Opportunity Announcement (FOA) invites researchers to submit R03 or R21 applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Deadline: Application due by January 7, 2019.



McKnight Scholar Awards in Neuroscience
Sponsor: McKnight Endowment Fund for Neuroscience
Description: The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain and behavior can be accurately diagnosed, prevented, and treated. Scholars will receive $75,000 annually in 2019, 2020 and 2021, subject to an annual review of research progress.
Deadline: Application due by January 7, 2019.



Fay/Frank Seed Grant
Sponsor: Brain Research Foundation
Description: Brain Research Foundation is inviting eligible US institutions to nominate one faculty member to submit a Letter of Intent for the Fay/Frank Seed Grant Program by January 8, 2019. To be eligible, the PI must be a full-time Assistant or Associate Professor working in the field of neuroscience. The goal of the program is to providing start-up money for new and innovative research projects that have the potential to become competitive for an NIH grant or other external funding sources. Each total grant is limited to $80,000 (direct costs) for a two year grant period.
Deadline: Letter of Intent due by January 8, 2019.



Research Grants
Sponsor: Whitehall Foundation
Description: The Whitehall Foundation invites researchers to apply for their research grants. Funding priorities: basic research in neurobiology. Research grants are available to established scientists of all ages working at accredited institutions in the United States. The Foundation emphasizes the support of young scientists at the beginning of their careers and productive senior scientists who wish to move into new fields of interest. Research grants normally range from $30,000 to $75,000 per year.
Deadline: Letter of Intent due by January 15, 2019.



Warren Alpert Scholars – Fellowship Award (Neuroscience)
Sponsor: Warren Alpert Foundation
Description: This award will support individual scientists of exceptional creativity who have an MD or PhD degree and who have completed three years of post-doctoral fellowship in a medical school in the basic neurosciences. These awards are given as transitional post-doctoral awards for recipients before they later become a full time faculty member at the Assistant Professor level or higher. The Scholars will be awarded $200,000 annually for two years to cover their salary, lab costs, and related expenses.
Deadline: Application due by January 15, 2019.



Klingenstein-Simons Fellowship Awards in Neuroscience
Sponsor: The Esther A. and Joseph Klingenstein Fund
Description: The Klingenstein-Simons Fellowship Awards in the Neurosciences supports, in the early stages of their careers, young investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders. The award of $225,000 is payable over a three-year period. To qualify, researchers must have a tenure-track appointment or the equivalent and be based in the US.
Deadline: Application due by February 15, 2019.



Early Career Research Fellowship
Sponsor: Fight MND
Description: This Fellowship will support early-career researchers (within 5 years following award of their PhD) to lead a research project aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. A total of AUD $100,000 per annum for support of a 3-year full-time Fellowship, with an overall maximum of $300,000 for a 3-year award. Proposals for both discovery and translational research stages will be considered. Applications are invited for researchers based in institutions within Australia. Applicants must have completed their PhD within 5 years at the time of application.
Deadline: Application due by April 1, 2019.



IMPACT Grants
Sponsor: Fight MND
Description: IMPACT (IMProving and ACcelerating Translation) Grants support projects focused on one or more of the following key issues contributing to the lack of translation of effective treatments through to clinical trial for MND/ALS: disease heterogeneity; Lack of relevant preclinical models; a lack of reliable disease biomarkers; the challenge of drug delivery into the brain; a lack of effective targeted gene therapies; the untapped potential of stem cell therapy. These grants are for support of 2-year projects up to the value of AUD $250,000. Proposals for both discovery and translational research stages will be considered. Applications are invited for research based in institutions within Australia. Investigators at all academic levels are eligible to submit applications.
Deadline: Application due by April 1, 2019.



Mid-Career Research Fellowship
Sponsor: Fight MND
Description: This Fellowship will support mid-career researchers (5 – 12 years following award of their PhD) to lead a research project aimed at understanding the causes of MND/ALS, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. A total of AUD $100,000 per annum for support of a 3-year full-time Fellowship, with an overall maximum of $300,000 for a 3-year award. Proposals for both discovery and translational research stages will be considered. Applications are invited for researchers based in institutions within Australia. Applicants must have completed their PhD within 5 – 12 years at the time of application.
Deadline: Application due by April 1, 2019.



CLIN 1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion an IND or IDE filing with the FDA and initiate clinical trial start-up with a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $6M USD. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 18 months.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of a clinical trial for a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $10-15M USD.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 3: Partnering Opportunity for Stem Cell Therapy Registration Clinical Trials
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded clinical trial projects that will directly enable product registration with the Food and Drug Administration (FDA). This award is only available to holders of a current CLIN2 award for a trial that has been deemed by FDA to be sufficient for registration.
Deadline: Applications due by 2PM PST on the the last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clinical Neuroscience Research Grants
Sponsor: Dana Foundation
Description: This grant funds "first-in-man" clinical studies of therapies being developed for brain diseases. Funded studies can receive up to $300,000 payable over three years. Potential applicants may submit a preliminary proposal and budget to determine full proposal eligibility. Applications are not solely restricted to clinical research scientists based in the United States.
Deadline: Applications are accepted on a rolling basis.



DISC 2: The Quest Awards (Stem Cells)
Sponsor: California Institute for Regenerative Medicine (CIRM)
Description: This award program promotes the discovery of promising new stem cell-based technologies that could be translated to enable broad use and ultimately, improve patient care. Projects funded through the Quest Awards should propose technology that is uniquely enabled by human stem/progenitor cells or directly reprogrammed cells, or uniquely enabling for the advancement of stem cell-based therapies. Up to $500,000 USD will be awarded to achieve a candidate that is a diagnostic, a medical device or a tool; or up to $900,000 USD per award to achieve a candidate that is a therapeutic.
Deadline: TBD.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Applications are accepted on a rolling basis.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail